NeoGenomics Inc (NEO) Stock Up 3.5% but GF Value Says Overvalued -- GF Score: 73/100

gurufocus.com · 2026-08-26

Valuation Assessment of NeoGenomics Inc (NEO)On August 26, 2026, NeoGenomics Inc (NEO) shares rose 3.5% today, closing at $17.37. The stock has experienced a no

TickrTrends take: NeoGenomics trades in the Healthcare sector where valuation metrics carry particular weight given the industry's sensitivity to clinical validation and reimbursement changes. With TickrTrends currently awaiting full valuation for NEO, the recent stock movement paired with GF Value's overvaluation assessment suggests that investors focused on valuation should monitor whether the company's fundamentals can support its current price level. A valuation-focused reader should track whether upcoming earnings or clinical developments provide justification for the stock's positioning or whether valuation pressure may intensify.

Read the full story at gurufocus.com →